As reduced brain volume and dysfunction are observed in AD patients (Teipel et al., 2006; Wang et al., 2020), OD can contribute to the development of AD through mechanisms such as Tau deposition, reduced neurotransmitter secretion, and decreased BDNF expression, all resulting from neurodegeneration. Here, MAPT is linked to Alzheimer disease.